MustGrow Biologics Corp. is a fully integrated provider of biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, it offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. It develops mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Its TerraSante is Organic Materials Review Institute (OMRI Listed) and Organic Input Material (OIM) registered biofertility product in California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSante provides mustard proteins and carbohydrates to feed the soil microbes.

Employees

Sector

Biotechnology & Medical Research

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4750CAD

Average target price

2.700CAD

Spread / Average Target

+468.42%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Canadian Securities Exchange			5-day change	1st Jan Change
- ^CAD	-.--%		+6.74%	-28.57%

08-27	MustGrow Biologics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	MustGrow Biologics Secures First Milestone Payment from Bayer	MT

Market Cap	33.46M 24.08M 20.75M 19.46M 17.76M 2.3B 33.57M 231M 90.07M 1.16B 90.42M 88.45M 3.85B	P/E 2026 *	-6.79x	P/E 2027 *	-23.8x
Enterprise Value	33.46M 24.08M 20.75M 19.46M 17.76M 2.3B 33.57M 231M 90.07M 1.16B 90.42M 88.45M 3.85B	EV / Sales 2026 *	7.44x	EV / Sales 2027 *	2.38x
Free-Float	90.82%	Yield 2026 *	-	Yield 2027 *	-

08-27	MustGrow Biologics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	MustGrow Biologics Secures First Milestone Payment from Bayer	MT
08-21	Mustgrow Biologics Corp. Receives First Milestone Payment from Bayer Ag Under License and Collaboration Agreement	CI
06-18	MustGrow Biologics Corp. announced that it has received CAD 3.740771 million in funding	CI
05-28	MustGrow Biologics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-26	MustGrow Biologics Launches C$2 Million Non-Brokered Private Placement of Units	MT
05-25	Mustgrow Biologics Corp Receives Texas, Utah, and Montana Registrations for Terrasante Biofertility Product	CI
05-24	MustGrow Biologics Corp. announced that it expects to receive CAD 2 million in funding	CI
04-29	MustGrow Biologics Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	Mustgrow Biologics Corp Receives Georgia Registration for Terrasante Biofertility Product	CI
04-27	MustGrow Receives Georgia Registration for TerraSante Biofertility Product	CI
04-07	MustGrow Biologics Corp. Announces to Close Its Wholly-Owned Canadian Marketing and Distribution Business NexusBioAg Effective April 15, 2026	CI
02-03	Mustgrow Biologics Corp. Announces Completion and Results of Its 2-Year Field Trial Program in the Canadian Prairies on Approximately 100 Acres of Canola Production	CI

08-27	MustGrow Announces Second Quarter 2026 Financial Results	NE
08-24	Market One: MustGrow Biologics Receives First Bayer Milestone Payment	NE
08-24	MustGrow Receives First Milestone Payment from Bayer AG	AQ
08-21	MustGrow Receives First Milestone Payment from Bayer AG	NE
06-26	MustGrow Biologics Corp. Announces Results of Shareholder Meeting	NE

MustGrow Biologics Corp. Stock Canadian Securities Exchange

Stocks

MGRO

CA62822A1030

Biotechnology & Medical Research

Valuation : MustGrow Biologics Corp.

Latest news : MustGrow Biologics Corp.

Press Releases : MustGrow Biologics Corp.

News in other languages : MustGrow Biologics Corp.

Managers and Directors : MustGrow Biologics Corp.

Other Biotechnology & Medical Research

Financials

Company Profile

Analysts' Consensus

Quarterly revenue - Rate of surprise

Manager	Title	Age	Since
Corey Giasson CEO	Chief Executive Officer	48	2018-03-14
Todd Lahti DFI	Director of Finance/CFO	60	2018-12-16
Colin Bletsky COO	Chief Operating Officer	51	2018-08-31

Director	Title	Age	Since
Corey Giasson BRD	Director/Board Member	48	2018-03-14
Brad Munro CHM	Chairman	66	2018-03-14
Colin Bletsky BRD	Director/Board Member	51	2018-03-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MUSTGROW BIOLOGICS CORP.	-.--%	+6.74%	-	-	24.08M
LONZA GROUP AG	-0.78%	-1.42%	+2.96%	+21.65%	50.47B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+447.48%	+535.14%	44.56B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+37.18%	+16.26%	43.08B
BEONE MEDICINES AG	-1.55%	-2.07%	+19.83%	+71.70%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+19.47%	+48.24%	33.21B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+26.32%	+125.06%	16.77B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.63%	+27.62%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.49%	+42.97%	13.92B
Average	-1.38%	-1.06%	+80.42%	+111.08%	30.51B
Weighted average by Cap.	-1.70%	-1.06%	+96.28%	+129.03%

	2026 *	2027 *
Net sales	4.5M 3.24M 2.79M 2.62M 2.39M 310M 4.51M 31.05M 12.11M 156M 12.16M 11.9M 518M	14.05M 10.11M 8.71M 8.17M 7.46M 966M 14.09M 96.93M 37.82M 488M 37.97M 37.14M 1.62B
Net income	-4.68M -3.37M -2.9M -2.72M -2.48M -322M -4.69M -32.29M -12.6M -163M -12.65M -12.37M -539M	-1.45M -1.04M -899K -843K -770K -99.74M -1.45M -10M -3.9M -50.35M -3.92M -3.83M -167M
Net Debt	-	-